-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VnFOUZDw/vERuA1DRBiSVFjqxU5scPC1LY/GNj2MbbUnuzhyIfQ6wdX0HMB8A158
 3/FTK4HtiNYgPxgri3i3dg==

<SEC-DOCUMENT>0001295345-06-000129.txt : 20061016
<SEC-HEADER>0001295345-06-000129.hdr.sgml : 20061016
<ACCEPTANCE-DATETIME>20061016144709
ACCESSION NUMBER:		0001295345-06-000129
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20061016
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
FILED AS OF DATE:		20061016
DATE AS OF CHANGE:		20061016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SHEFFIELD PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		061146027

	BUSINESS ADDRESS:	
		STREET 1:		1220 GLENMORE DRIVE
		CITY:			APOPKA
		STATE:			FL
		ZIP:			32712
		BUSINESS PHONE:		407-880-2213

	MAIL ADDRESS:	
		STREET 1:		1220 GLENMORE DRIVE
		CITY:			APOPKA
		STATE:			FL
		ZIP:			32712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19940606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sfph.htm
<DESCRIPTION>CURRENT REPORT ON FORM 8-K
<TEXT>
<html>

<head>
<title>sfph</title>
</head>

<body>
<div>

<hr SIZE="4" NOSHADE COLOR="#000000">

<hr SIZE="2" NOSHADE COLOR="#000000">

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="4"><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</b></font></p>

<p ALIGN="CENTER"><b><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="3">Washington, D.C.
20549<br>
</font></b></p>

<p ALIGN="CENTER"><font SIZE="4" FACE="Times New Roman, Times, Serif">___________________<br>
<br>
<strong>FORM 8-K<br>
</strong>___________________</font></p>

<p align="center"><font size="3"><b>CURRENT REPORT</b> </font></p>

<p align="center"><font size="2"><b>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934</b> </font></p>

<p align="center"><font size="2">Date of report (date of earliest event reported): Ocotber
16, 2006 </font></p>

<p ALIGN="CENTER">&nbsp;</p>

<p style="FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt; COLOR: windowtext; TEXT-ALIGN: center"
align="center"><font face="Times New Roman" size="2">Commission file number: 01-12584</font></p>

<p style="FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt; COLOR: windowtext; TEXT-ALIGN: center"
align="center">&nbsp;</p>

<p ALIGN="center"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="5"><b>SHEFFIELD
PHARMACEUTICALS, INC.<br>
</b></font><font face="TIMES NEW ROMAN, TIMES, SERIF" size="1">(Exact Name Of Registrant
As Specified In Its Charter)</font></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td width="50%" align="center"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>Delaware</u></font></td>
    <td width="50%" align="center"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>13-3808303</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ccffcc"><font size="1">(State of Incorporation)</font></td>
    <td width="50%" align="center" bgcolor="#ccffcc"><font size="1">(I.R.S. Employer
    Identification No.)</font></td>
  </tr>
  <tr>
    <td width="50%" align="center">&nbsp; </td>
    <td width="50%" align="center">&nbsp; </td>
  </tr>
  <tr>
    <td width="50%" align="center"><font size="2">1576 Bella Cruz Drive, Suite 322, The
    Villages, FL</font></td>
    <td width="50%" align="center"><font size="2"><u>32159</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ccffcc"><font size="1">(Address of Principal
    Executive Offices)</font></td>
    <td width="50%" align="center" bgcolor="#ccffcc"><font size="1">(ZIP Code)</font></td>
  </tr>
</table>

<p align="center"><font size="2">&nbsp;Registrant's Telephone Number, Including Area Code:
(352) 750-0751</font></p>

<p><font size="2">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):</font></p>

<p><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) <br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Soliciting material
pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</font></p>

<hr SIZE="2" NOSHADE COLOR="#000000">

<hr SIZE="4" NOSHADE COLOR="#000000">
</div>

<p><br clear="all" style="page-break-before:always; mso-break-type:section-break">
</p>
<div>

<p align="justify"><font size="2"><strong>ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL
OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS</strong></font></p>

<p align="justify"><font size="2">On October 13, 2006, the Registrant's board of directors
appointed Nicholas Stergis, M.S. to the board of directors.</font></p>
<font size="2">

<p ALIGN="JUSTIFY"><em>Nicholas Stergis, M.S</em>. Mr. Stergis is co-founder and Managing
Director of Accredited Ventures Inc., a venture capital firm specializing in the
biotechnology and pharmaceutical industries. Mr. Stergis is also Managing Director of
Accredited Equities, Inc., an NASD member firm. </p>

<p ALIGN="JUSTIFY">Mr. Stergis is co-founder, Chief Operating Officer and a member of the
board of directors of Pipex Therapeutics, Inc. Prior to co-founding Pipex, Mr. Stergis was
a co-founder, Chief Operating Officer and director of Developmental Therapeutics, Inc.,
cardiovascular drug development company, until its acquisition in October 2003, by Titan
Pharmaceuticals, Inc. (AMEX:TTP), a publicly-traded pharmaceutical company.</p>

<p ALIGN="JUSTIFY">Prior to co-founding Accredited Ventures, Mr. Stergis was the Interim
Director of Corporate Development for Corporate Technology Development, Inc. (CTD), a
biopharmaceutical company based in Miami, Florida, until its merger with DOR BioPharma,
Inc. (DOR), a publicly traded biotechnology company. During his tenure at CTD, he was
responsible for all development tasks associated with the company&#146;s lead product,
orBec&#174, which has completed a pivotal Phase III clinical trial and is pending NDA
submission. He was also instrumental in CTD&#146;s divestiture of important botulinum
toxin intellectual property to Allergan, Inc. (NYSE:AGN), a publicly traded specialty
pharmaceutical companies. Prior to joining CTD, Mr. Stergis was a Technology Associate at
Paramount Capital, a New York based, private equity, venture capital, investment banking
and asset management group specializing in the biotechnology and pharmaceutical
industries. There, he participated in the startup, acquisition and financing of various
biotechnology companies, including CTD. </p>

<p ALIGN="JUSTIFY">Mr. Stergis received his M.S. in Biology from New York University as
well as a B.S. in Biology from the University at Albany, State University of New York. Mr.
Stergis is also a director and officer of several privately held biopharmaceutical
companies which are engaged in the in-licensing of biopharmaceutical candidates.</font></p>

<p ALIGN="CENTER"><font size="2">SIGNATURES</font></p>

<p ALIGN="JUSTIFY"><font size="2">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></p>

<table border="0" cellspacing="0" width="100%">
  <tr>
    <td width="100%"><font size="2">Sheffield Pharmaceuticals, Inc.</font></td>
  </tr>
  <tr>
    <td width="100%"><font size="2">By: /s/ Michael F. Manion, CEO, CFO and Chairman</font></td>
  </tr>
  <tr>
    <td width="100%">&nbsp; </td>
  </tr>
  <tr>
    <td width="100%"><font size="2">Date: October 16, 2006</font></td>
  </tr>
</table>

<p align="left">&nbsp;</p>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
